$NVLX Headlines 10-Q: NUVILEX, INC. 6:07 a.m. De
Post# of 102254
Posted On: 12/19/2013 2:43:17 PM
$NVLX Headlines
10-Q: NUVILEX, INC. 6:07 a.m. Dec. 16, 2013 - Edgar Online - (EDG = 10Q, 10K)
Newly Transformed Nuvilex To Enjoy Strong 2014 11:33 a.m. Dec. 10, 2013 - Seeking Alpha
Nuvilex Names Kenneth L. Waggoner as President and CEO 9:18 a.m. Nov. 25, 2013 - benzinga.com
An Ongoing Debate: Is Nuvilex For Real? 2:19 p.m. Nov. 5, 2013 - Seeking Alpha
10-Q: NUVILEX, INC. 5:03 a.m. Sept. 16, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: NUVILEX, INC. 3:21 p.m. July 29, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: NUVILEX, INC. 5:14 a.m. March 26, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: NUVILEX, INC. 4:49 p.m. Dec. 26, 2012 - Edgar Online - (EDG = 10Q, 10K)
Nuvilex's Provides Progress Update on Cell Cloning Being Performed by Inno Biologics 9:30 a.m. Today - GlobeNewswire
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine 9:15 a.m. Dec. 16, 2013 - Marketwire
Nuvilex's Preparations for Planned Late-Phase Clinical Trials Timely in Light of Increasing Incidence of Pancreatic Cancer 9:30 a.m. Dec. 12, 2013 - GlobeNewswire
Nuvilex's (NVLX) Acquisition of Cellulose-based Live-Cell Encapsulation Technology Positions Company as a Leader in Development of Next Generation Cancer and Diabetes Treatments 8:30 a.m. Dec. 12, 2013 - ACCESSWIRE
Nuvilex's Contractor, Inno Biologics, Employs Clone-Pix(TM) Technology in Cloning Cells for Future Clinical Trials 9:30 a.m. Dec. 11, 2013 - GlobeNewswire
Nuvilex Holds High Level Strategic Meetings to Solidify Company Objectives and Plans for Future Research and Development 9:30 a.m. Dec. 9, 2013 - GlobeNewswire
Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc., Appoints Dr. Mark L. Rabe as Chairman of Its Scientific Advisory Board 9:30 a.m. Dec. 6, 2013 - GlobeNewswire
After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment 9:15 a.m. Dec. 5, 2013 - Marketwire
Record Diabetes Cases Highlight Need for Nuvilex Treatment 8:45 a.m. Dec. 4, 2013 - Marketwire
Nuvilex Ahead of the Curve on Cannabidiol as FDA Issues Landmark Approval 8:30 a.m. Nov. 29, 2013 - Marketwire
Nuvilex Accelerates Development of Treatments for Cancer and Diabetes With New Corporate Management Structure 10:15 a.m. Nov. 25, 2013 - GlobeNewswire
Nuvilex's Acquisition of Diabetes Rights Should Put the Company on Everyone's Radar 8:31 a.m. Nov. 19, 2013 - Marketwire
Nuvilex: The Triple Threat 9:30 a.m. Nov. 13, 2013 - Marketwire
Detailed Coverage on NVLX, PGLO, LIFS and DROP 2:02 a.m. Nov. 13, 2013 - ACCESSWIRE
Investors Confidently Back Nuvilex's Acquisition of Diabetes Technology 8:45 a.m. Nov. 12, 2013 - Marketwire
In Depth Coverage on SEEK, NVLX, SGLB and LQMT 1:43 a.m. Nov. 11, 2013 - ACCESSWIRE
Nuvilex Advances Company Toward Future Clinical Treatments Through Successful Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes 10:30 a.m. Nov. 8, 2013 - GlobeNewswire
Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes 9:30 a.m. Nov. 7, 2013 - GlobeNewswire
Detailed Insight on NVLX, ENIP, CBIS and FARE 1:20 a.m. Nov. 6, 2013 - ACCESSWIRE
Nuvilex, Inc. Reaches Unofficial Starting Line of Its Phase 3 Pancreatic Cancer Clinical Trials 8:30 a.m. Nov. 5, 2013 - Marketwire
10-Q: NUVILEX, INC. 6:07 a.m. Dec. 16, 2013 - Edgar Online - (EDG = 10Q, 10K)
Newly Transformed Nuvilex To Enjoy Strong 2014 11:33 a.m. Dec. 10, 2013 - Seeking Alpha
Nuvilex Names Kenneth L. Waggoner as President and CEO 9:18 a.m. Nov. 25, 2013 - benzinga.com
An Ongoing Debate: Is Nuvilex For Real? 2:19 p.m. Nov. 5, 2013 - Seeking Alpha
10-Q: NUVILEX, INC. 5:03 a.m. Sept. 16, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: NUVILEX, INC. 3:21 p.m. July 29, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: NUVILEX, INC. 5:14 a.m. March 26, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: NUVILEX, INC. 4:49 p.m. Dec. 26, 2012 - Edgar Online - (EDG = 10Q, 10K)
Nuvilex's Provides Progress Update on Cell Cloning Being Performed by Inno Biologics 9:30 a.m. Today - GlobeNewswire
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine 9:15 a.m. Dec. 16, 2013 - Marketwire
Nuvilex's Preparations for Planned Late-Phase Clinical Trials Timely in Light of Increasing Incidence of Pancreatic Cancer 9:30 a.m. Dec. 12, 2013 - GlobeNewswire
Nuvilex's (NVLX) Acquisition of Cellulose-based Live-Cell Encapsulation Technology Positions Company as a Leader in Development of Next Generation Cancer and Diabetes Treatments 8:30 a.m. Dec. 12, 2013 - ACCESSWIRE
Nuvilex's Contractor, Inno Biologics, Employs Clone-Pix(TM) Technology in Cloning Cells for Future Clinical Trials 9:30 a.m. Dec. 11, 2013 - GlobeNewswire
Nuvilex Holds High Level Strategic Meetings to Solidify Company Objectives and Plans for Future Research and Development 9:30 a.m. Dec. 9, 2013 - GlobeNewswire
Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc., Appoints Dr. Mark L. Rabe as Chairman of Its Scientific Advisory Board 9:30 a.m. Dec. 6, 2013 - GlobeNewswire
After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment 9:15 a.m. Dec. 5, 2013 - Marketwire
Record Diabetes Cases Highlight Need for Nuvilex Treatment 8:45 a.m. Dec. 4, 2013 - Marketwire
Nuvilex Ahead of the Curve on Cannabidiol as FDA Issues Landmark Approval 8:30 a.m. Nov. 29, 2013 - Marketwire
Nuvilex Accelerates Development of Treatments for Cancer and Diabetes With New Corporate Management Structure 10:15 a.m. Nov. 25, 2013 - GlobeNewswire
Nuvilex's Acquisition of Diabetes Rights Should Put the Company on Everyone's Radar 8:31 a.m. Nov. 19, 2013 - Marketwire
Nuvilex: The Triple Threat 9:30 a.m. Nov. 13, 2013 - Marketwire
Detailed Coverage on NVLX, PGLO, LIFS and DROP 2:02 a.m. Nov. 13, 2013 - ACCESSWIRE
Investors Confidently Back Nuvilex's Acquisition of Diabetes Technology 8:45 a.m. Nov. 12, 2013 - Marketwire
In Depth Coverage on SEEK, NVLX, SGLB and LQMT 1:43 a.m. Nov. 11, 2013 - ACCESSWIRE
Nuvilex Advances Company Toward Future Clinical Treatments Through Successful Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes 10:30 a.m. Nov. 8, 2013 - GlobeNewswire
Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes 9:30 a.m. Nov. 7, 2013 - GlobeNewswire
Detailed Insight on NVLX, ENIP, CBIS and FARE 1:20 a.m. Nov. 6, 2013 - ACCESSWIRE
Nuvilex, Inc. Reaches Unofficial Starting Line of Its Phase 3 Pancreatic Cancer Clinical Trials 8:30 a.m. Nov. 5, 2013 - Marketwire
(0)
(0)Scroll down for more posts ▼